Lawsuit Filed Against Altimmune, Inc. for Securities Fraud

A securities fraud class action has been filed against Altimmune, Inc. (ALT), reminding investors of the deadline on October 6, 2025. The lawsuit alleges that Altimmune made false and misleading statements regarding the efficacy of its COVID-19 vaccine candidate, causing investors to suffer losses.

According to the class action lawsuit, Altimmune misled investors by claiming that its COVID-19 vaccine candidate, AdCOVID, showed promising results in preclinical studies and that it was highly effective in producing an immune response. However, the lawsuit alleges that Altimmune failed to disclose that the vaccine was not as effective as claimed, leading to its stock price being artificially inflated.

As a result of these alleged false and misleading statements, investors who purchased Altimmune’s stock suffered financial losses when the truth about the vaccine’s efficacy came to light. The lawsuit seeks to recover damages for investors who were harmed by Altimmune’s alleged securities fraud.

Investors who purchased Altimmune stock between August 24, 2021, and July 19, 2022, are encouraged to join the class action lawsuit before the October 6, 2025 deadline. By participating in the lawsuit, investors may be able to recover some or all of their losses sustained as a result of Altimmune’s alleged securities fraud.

Altimmune investors who wish to participate in the class action lawsuit are advised to contact the law firm handling the case for more information on how to join. The lawsuit aims to hold Altimmune accountable for its alleged securities fraud and recover losses for investors who were misled by the company’s false and misleading statements.

In conclusion, investors who suffered losses due to Altimmune’s alleged securities fraud have the opportunity to seek justice and potentially recover damages by joining the class action lawsuit. The deadline for investors to participate in the lawsuit is October 6, 2025, and those affected are encouraged to take action to hold Altimmune accountable for its actions.